Rosiglitazone Regulates Anti-Inflammation and Growth Inhibition via PTEN

Peroxisome proliferator-activated receptor gamma (PPARγ) agonist has anti-inflammatory and anticancer properties. However, the mechanisms by which PPARγ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear. We found...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2014-01, Vol.2014 (2014), p.1-14
Main Authors: Lin, Chiou-Feng, Young, Kung-Chia, Bai, Chyi-Huey, Yu, Bu-Chin, Ma, Ching-Ting, Chien, Yu-Chieh, Chiang, Chiu-Ling, Liao, Chao-Sheng, Lai, Hsin-Wen, Tsao, Chiung-Wen
Format: Article
Language:English
Subjects:
Animals
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Apoptosis
Biomedical research
Cell growth
Cell Line
COX-2 inhibitors
Cyclooxygenase 2 - genetics
Cyclooxygenase 2 - metabolism
G1 Phase Cell Cycle Checkpoints - drug effects
G1 Phase Cell Cycle Checkpoints - genetics
Hospitals
Hypoglycemic Agents - pharmacology
Inflammation
Kinases
Ligands
Lipopolysaccharides - toxicity
Macrophages - metabolism
Macrophages - pathology
Mice
Nitric Oxide - genetics
Nitric Oxide - metabolism
PPAR gamma - agonists
PPAR gamma - genetics
PPAR gamma - metabolism
Proteins
Proto-Oncogene Proteins c-akt - genetics
Proto-Oncogene Proteins c-akt - metabolism
PTEN Phosphohydrolase - genetics
PTEN Phosphohydrolase - metabolism
Reactive Oxygen Species - metabolism
Rodents
Rosiglitazone maleate
Studies
Technological change
Thiazolidinediones
Thiazolidinediones - pharmacology
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peroxisome proliferator-activated receptor gamma (PPARγ) agonist has anti-inflammatory and anticancer properties. However, the mechanisms by which PPARγ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear. We found that lower doses (
ISSN:2314-6133
2314-6141
DOI:10.1155/2014/787924